Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipragliflozin in Type 2 Diabetes
NCT02791035Phase 4Completed
- Sponsor
- Asan Medical Center
- Start
- Jun 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ipragliflozin in type 2 diabetes mellitus (T2DM), sponsored by Asan Medical Center. Primary endpoint: Correlation between change of HbA1c and urinary glucose excretion at 12 weeks. Started Jun 2016; status: completed.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02791035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02791035.